QGEN — QIAGEN N.V.

NYSE · Health Care · Biotechnology · CIK 1015820 · Netherlands
Last close
$35.54
Market Cap
$7.33B
52W High
$49.86
52W Low
$32.53
ADV30
2,249,681
Next earnings
2026-08-04
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 492,320,000 309,603,000 116,626,000 68,043,000 5,782,065,000 646,289,000 2,450,359,000
Dec 2025 540,420,000 325,269,000 121,880,000 107,829,000 6,281,232,000 839,005,000 2,503,078,000
Sep 2025 532,583,000 331,259,000 137,293,000 130,043,000 6,553,497,000 1,355,594,000 2,904,082,000
Jun 2025 533,540,000 334,286,000 135,974,000 96,250,000 5,823,758,000 733,815,000 2,318,268,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$654,326,000
Investing CF
$-305,279,000
Financing CF
$-178,976,000
CapEx
$-207,126,000
Dividends Paid
$1,000
Buybacks
$0
EPS Diluted TTM
$2.04
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$2,748,390,000
Inventory
$301,888,000
Receivables
$520,033,000
ST Investments
$259,913,000
EBIT TTM
$523,521,000
Pretax Income TTM
$490,265,000
Interest Exp TTM
$33,256,000
Analysts
14

Yahoo Snapshot (yfinance, live)

Total Revenue
$2,098,862,976
EBITDA
$727,684,992
Free Cash Flow
$238,874,368
Enterprise Value
$8,274,586,624
Total Cash
$646,289,024
Total Debt
$1,667,063,040
Shares Out
206,250,000
Trailing EPS
$1.96
Book Value
$16.15
ROE
11.9%
ROA
6.0%
Div Yield
1.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 2,089,999,000 520,310,000 424,880,000 6,281,232,000 2,503,078,000 654,326,000
Dec 2024 1,978,214,000 199,899,000 83,591,000 5,689,622,000 2,122,283,000 673,551,000
Dec 2023 1,965,311,000 445,247,000 341,303,000 6,115,190,000 2,307,426,000 459,455,000
Dec 2022 2,141,518,000 576,228,000 423,211,000 6,287,735,000 2,821,124,000 715,264,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$2.64

Max Pain — expiry 2026-06-18

max pain strike: $35.00 · spot: $35.54 · call oi: 11,858 · put oi: 1,319
Expected Move to 2026-06-18: ±$2.73 (7.67%) — implied range $32.82$38.27 · ATM straddle on $35.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
PCVX Vaxcyte, Inc. $7.24B $50.11
TECH BIO-TECHNE Corp $7.51B $47.97
IMVT Immunovant, Inc. $6.95B $33.83
KYMR Kymera Therapeutics, Inc. $6.64B $80.77
HALO HALOZYME THERAPEUTICS, INC. $8.15B $68.72

News headlines (Yahoo Finance, 1h cache)

[Latest] Global Genome Editing Market Size/Share Worth USD 55.7 Billion by 2035 at a 17.4% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate,
2026-05-21 17:30 · Yahoo
NVIDIA Qiagen Alliance Extends AI Reach Into Drug Discovery Workflows
2026-05-21 13:15 · Yahoo
QIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflows
2026-05-20 20:05 · Yahoo
Abbott's Biosimilar Push to Help Sustain EPD Growth Momentum
2026-05-20 12:37 · Yahoo
3 Stocks in Focus That Recently Declared Dividend Hikes Amid High Inflation
2026-05-20 12:33 · Yahoo
QIAGEN and NVIDIA partner on AI drug discovery
2026-05-20 10:22 · Yahoo
QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA
2026-05-19 20:05 · Yahoo
Nucleic Acid Isolation and Purification Market Report 2026-2030: Trends, Challenges and Competitive Analysis Featuring Thermo Fisher Scientific, Merck, QIAGEN, and Roche
2026-05-12 15:13 · Yahoo
QIAGEN to Appoint Dr. Metin Colpan as Honorary Chairman of the Supervisory Board, Continue Governance Renewal and Propose Increased Returns at 2026 Annual General Meeting
2026-05-12 06:00 · Yahoo
Deciphering Qiagen (QGEN) International Revenue Trends
2026-05-11 13:15 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.